MoonLake Immunotherapeutics (MLTX) Equity Ratio (2020 - 2026)

MoonLake Immunotherapeutics' Equity Ratio history runs 7 years deep, the most recent figure standing at 0.63 for Q1 2026.

• In Q1 2026, Equity Ratio fell 21.38% year-over-year to 0.63; the TTM figure through Mar 2026 stood at 0.63 (down 21.38% YoY), while the FY2025 annual figure was 0.72, down 23.27% from the prior year.
• Equity Ratio was 0.63 for Q1 2026 at MoonLake Immunotherapeutics, down from 0.72 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.99 in Q2 2023 to a low of 0.11 in Q1 2022.
• Historically, Equity Ratio has averaged 0.82 across 5 years, with a median of 0.93 in 2022.
• Biggest YoY gain for Equity Ratio was 13390.28% in 2022; the steepest drop was 5092.45% in 2022.
• A 5-year view of Equity Ratio shows it stood at 0.89 in 2022, then gained by 8.98% to 0.98 in 2023, then fell by 4.13% to 0.93 in 2024, then fell by 23.27% to 0.72 in 2025, then dropped by 11.56% to 0.63 in 2026.
• The last three Equity Ratio figures came in at 0.63 (Q1 2026), 0.72 (Q4 2025), and 0.7 (Q3 2025), per Business Quant data.